Ultragenyx Pharmaceutical Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 90.7 million compared to USD 81.65 million a year ago. Net loss was USD 245.11 million compared to USD 73 million a year ago. Basic loss per share from continuing operations was USD 3.5 compared to USD 1.08 a year ago.
For the nine months, revenue was USD 259.98 million compared to USD 268.02 million a year ago. Net loss was USD 555.59 million compared to USD 331.57 million a year ago. Basic loss per share from continuing operations was USD 7.96 compared to USD 4.91 a year ago.